This recombinant monoclonal antibody is developed as a research-grade biosimilar to Exlinkibart, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and cytotoxic function. Upon binding to its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that amplify immune responses. This pathway has significant implications in cancer immunotherapy, autoimmune diseases, and viral infections, where modulation of T cell activation can influence disease outcomes.
Exlinkibart represents an investigational agonistic antibody designed to stimulate TNFRSF9 signaling and enhance anti-tumor immunity. This biosimilar antibody provides researchers with a valuable tool for investigating TNFRSF9-mediated immune activation mechanisms, exploring combination immunotherapy strategies, and studying T cell costimulation in various disease models. The antibody supports preclinical research into immune checkpoint modulation and the development of novel therapeutic approaches targeting the TNFRSF9 pathway.
Email: support@cusabio.com
Distributors Worldwide